Equities

Medipal Holdings Corp

Medipal Holdings Corp

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (JPY)2,182.00
  • Today's Change25.00 / 1.16%
  • Shares traded444.10k
  • 1 Year change+1.58%
  • Beta0.6940
Data delayed at least 20 minutes, as of Sep 24 2021 07:00 BST.
More ▼
Take Survey
Help shape our future virtual events & community services
Take part in our survey for a chance to win a free 3-month standard gift subscription.

Profile data is unavailable for this security.

About the company

MEDIPAL HOLDINGS CORPORATION engages in the wholesale of pharmaceutical products, cosmetics and daily miscellaneous goods. The Company operates in three segments. The Ethical Pharmaceutical Wholesale segment is involved in the wholesale of pharmaceutical products, medical equipment and test reagents, the distribution and planning of specialty drugs, the construction of medical material database and others. The Cosmetics, Daily Product and General Medicine Wholesale segment is engaged in the wholesale of cosmetics, daily miscellaneous goods and general pharmaceuticals. The Veterinary Medicine and Food Processing Raw Materials Wholesale segment is engaged in the wholesale of veterinary products, food additives and food raw materials. The Company is also involved in the provision of cleaning services, the management and operation of logistics centers, the provision of manpower dispatching services and others.

  • Revenue in JPY (TTM)3.24tn
  • Net income in JPY26.47bn
  • Incorporated1923
  • Employees12.97k
  • Location
    Medipal Holdings Corp2-7-15, YaesuCHUO-KU 104-8461JapanJPN
  • Phone+81 335175800
  • Fax+81 335175028
  • Websitehttps://www.medipal.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tsumura & Co130.89bn16.68bn287.08bn3.83k17.161.2811.462.19217.97217.971,710.762,922.860.40930.72522.6634,173,890.005.045.136.256.1955.7858.0212.3211.692.53--0.180633.606.193.0511.384.074.010.00
Hisamitsu Pharmaceutical Co Inc117.39bn11.50bn361.95bn2.77k30.231.3622.803.08140.60140.601,435.283,118.640.39332.573.3942,378,700.003.955.944.406.7760.1162.1710.0412.636.73--0.005439.53-18.78-6.69-50.52-12.25-8.030.8601
JCR Pharmaceuticals Co Ltd34.72bn7.66bn379.59bn732.0047.469.3039.4510.9361.6761.67279.63314.850.52340.67133.9847,427,600.0011.548.2918.5710.6875.7969.8522.0515.611.16--0.316426.8821.4011.52157.3630.9639.7118.13
TAKARA BIO INC.54.42bn15.17bn386.53bn1.54k25.484.8120.447.10125.96125.96451.94668.000.62821.555.5335,360,620.0017.565.7720.256.3774.0761.3327.9611.662.71--0.0022.9533.339.16149.9948.2330.0954.80
Alfresa Holdings Corporation2.60tn22.03bn398.12bn12.05k16.280.737811.680.1533104.09104.0912,267.732,296.011.9216.154.29215,586,900.001.632.644.237.256.787.330.84791.321.07--0.001227.87-3.530.2069-39.16-6.875.049.94
ROHTO PHARMACEUTICAL CO., LTD.184.96bn19.54bn410.95bn6.60k20.382.4715.622.22170.78170.781,616.791,406.330.84282.384.6128,041,390.008.926.1312.008.7558.8659.4710.586.961.82--0.058722.70-3.741.658.6512.9716.856.96
Peptidream Inc11.45bn4.33bn485.59bn128.00112.1521.8998.7642.4133.3033.3088.90170.590.52013.7813.1889,445,060.0019.66--21.52--80.85--37.81--6.70--0.00--------------
Medipal Holdings Corp3.24tn26.47bn527.44bn12.97k18.250.856810.320.1627118.18118.1814,532.312,517.511.9320.264.57249,929,700.002.182.635.967.426.637.131.131.331.07--0.044925.33-1.291.18-36.98-4.91-16.418.45
Santen Pharmaceutical Co Ltd257.03bn8.02bn647.05bn4.23k80.912.0726.572.5219.9719.97642.22779.360.63732.532.9260,777,490.001.966.092.337.3260.9461.263.0710.212.2917.480.095944.963.335.03-71.10-33.7221.232.29
Nippon Shinyaku Co., Ltd.133.13bn27.21bn671.60bn2.06k23.673.7821.925.04403.96403.961,976.592,526.540.70351.493.1964,657,120.0014.399.6316.6711.4162.1755.5820.4514.214.04--0.0030.434.507.6822.7426.704.9328.73
Data as of Sep 24 2021. Currency figures normalised to Medipal Holdings Corp's reporting currency: Japanese Yen JPY

Institutional shareholders

16.43%Per cent of shares held by top holders
HolderShares% Held
Silchester International Investors LLPas of 18 May 202112.34m5.05%
Nomura Asset Management Co., Ltd.as of 15 Dec 20207.58m3.10%
The Vanguard Group, Inc.as of 03 Sep 20213.94m1.61%
Norges Bank Investment Managementas of 31 Dec 20203.38m1.38%
Daiwa Asset Management Co. Ltd.as of 31 Aug 20213.01m1.23%
Nikko Asset Management Co., Ltd.as of 02 Sep 20213.00m1.23%
BlackRock Fund Advisorsas of 02 Sep 20212.92m1.19%
Geode Capital Management LLCas of 16 Sep 20211.53m0.63%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 02 Sep 20211.45m0.59%
Morant Wright Management Ltd.as of 31 Mar 20211.01m0.41%
More ▼
Data from 31 Dec 2020 - 30 Jun 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
image